Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(4.20)
# 538
Out of 4,641 analysts
82
Total ratings
46.77%
Success rate
17.78%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.62 | +29.09% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $4.96 | +61.29% | 7 | Mar 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Hold | $25 | $14.29 | +74.95% | 15 | Dec 14, 2023 | |
| IMVT Immunovant | Initiates: Buy | $50 | $30.02 | +66.56% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $115.08 | +18.18% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.44 | +148.45% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $16.59 | +273.72% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $4.67 | +156.96% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $7.65 | +174.51% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $129.88 | -16.08% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.69 | +197.40% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $17 | $59.55 | -71.45% | 3 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.21 | +726.45% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.58 | +763.56% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $3.54 | +69.49% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.25 | +833.33% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $71.94 | -68.03% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $34.75 | +3.60% | 2 | Jul 11, 2017 |
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.62
Upside: +29.09%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $4.96
Upside: +61.29%
ACADIA Pharmaceuticals
Dec 14, 2023
Downgrades: Hold
Price Target: $25
Current: $14.29
Upside: +74.95%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $30.02
Upside: +66.56%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $115.08
Upside: +18.18%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.44
Upside: +148.45%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $16.59
Upside: +273.72%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $4.67
Upside: +156.96%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $7.65
Upside: +174.51%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $129.88
Upside: -16.08%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.69
Upside: +197.40%
Mar 9, 2023
Maintains: Buy
Price Target: $24 → $17
Current: $59.55
Upside: -71.45%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.21
Upside: +726.45%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.58
Upside: +763.56%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.54
Upside: +69.49%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.25
Upside: +833.33%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $71.94
Upside: -68.03%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $34.75
Upside: +3.60%